• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2011 NIHR Horizon Scanning Centre (NIHR HSC) Otamixaban for non-ST elevation acute coronary syndrome (NSTE ACS) - patients undergoing planned invasive treatment
2011 NIHR Horizon Scanning Centre (NIHR HSC) Prasugrel (Efient) for the prevention of atherothrombotic events in patients with acute coronary syndromes who will be managed without acute coronary revascularisation - in combination with aspirin
2011 NIHR Horizon Scanning Centre (NIHR HSC) Lu AA21004 for major depressive disorder
2011 NIHR Horizon Scanning Centre (NIHR HSC) Ocriplasmin (Microplasmin) for symptomatic vitreomacular adhesion (sVMA) - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Certolizumab pegol (Cimzia) for psoriatic arthritis - second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Infrared lasers for treating onychomycosis
2011 NIHR Horizon Scanning Centre (NIHR HSC) Golimumab (Simponi) for ulcerative colitis - second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Infliximab (Remicade) for paediatric ulcerative colitis
2011 NIHR Horizon Scanning Centre (NIHR HSC) Amniotic Fluid Lactate monitoring system for dysfunctional labour
2011 NIHR Horizon Scanning Centre (NIHR HSC) Placental growth factor based tests for the diagnosis of pre-eclampsia
2011 NIHR Horizon Scanning Centre (NIHR HSC) Everolimus (Afinitor) for advanced gastric cancer - second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) GSK1120212 for unresectable or metastatic melanoma, BRAF V600 mutation-positive in adults
2011 NIHR Horizon Scanning Centre (NIHR HSC) GSK2118436 (dabrafenib) for malignant melanoma: advanced and/or metastatic (stage III or IV), BRAF V600E mutation - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Regorafenib for metastatic colorectal cancer - third or fourth line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib (Nexavar) for hepatocellular carcinoma - adjuvant therapy
2011 NIHR Horizon Scanning Centre (NIHR HSC) Sorafenib (Nexavar) in combination with capecitabine for HER2-negative locally advanced or metastatic breast cancer - second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Exenatide (Byetta) for type 2 diabetes mellitus - in combination with basal insulin
2011 NIHR Horizon Scanning Centre (NIHR HSC) Aganirsen for pathological corneal neovascularisation
2011 NIHR Horizon Scanning Centre (NIHR HSC) Idebenone (Catena) for leber's hereditary optic neuropathy - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Defibrotide (Defitelio) for hepatic veno-occlusive disease in haematopoietic stem cell transplantation - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Certolizumab pegol (Cimzia) for active ankylosing spondylitis (AS) - second or third line; after intolerance or inadequate response to at least one non-steroidal anti-inflammatory drug (NSAID)
2011 NIHR Horizon Scanning Centre (NIHR HSC) Denosumab (Prolia) for osteoporosis in men
2011 NIHR Horizon Scanning Centre (NIHR HSC) Laquinimod for multiple sclerosis: relapsing-remitting - first or second line.
2011 NIHR Horizon Scanning Centre (NIHR HSC) Teriflunomide for relapsing multiple sclerosis (MS) - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Eculizumab (Soliris) for atypical haemolytic uraemic syndrome - first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Indacaterol/glycopyrronium (QVA-149) for chronic obstructive pulmonary disease
2011 Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of cancer-related secondary lymphedema]
2011 Institut national d'excellence en sante et en services sociaux (INESSS) [Organization of stroke care services]
2011 Institut national d'excellence en sante et en services sociaux (INESSS) [Home diagnosis of obstructive sleep apnea in children]
2011 Institut national d'excellence en sante et en services sociaux (INESSS) [Rare disease management: experiences from abroad]
2011 Medical Services Advisory Committee (MSAC) Review of interim funded service: Artificial intervertebral disc replacement - lumbar
2011 Health Council of the Netherlands Gezondheidsraad (GR) Q fever: risk of transmission via blood or other body material
2011 Health Council of the Netherlands Gezondheidsraad (GR) Antibiotics in food animal production and resistant bacteria in humans
2011 Health Council of the Netherlands Gezondheidsraad (GR) Malnutrition in the elderly
2011 The Regional Health Technology Assessment Centre (HTA-centrum) Bone anchored hearing aid in patients with unilateral hearing loss
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Surgical stabilization of a flail chest wall]
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2011 The Regional Health Technology Assessment Centre (HTA-centrum) Corneal crosslinking in keratoconus
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Laparoscopic surgery in kidney neoplasms]
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic surgery for benign gynecologic disease]
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Benefit of phrenic nerve stimulation for patients with complete traumatic lesion of the spinal cord and loss of spontaneous breathing]
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Effects on adherence to clinical guidelines by active 'on screen' computer-based clinical decision support systems]
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2011 Andalusian Health Technology Assessment Area (AETSA) [Biological therapies in the treatment of rheumatoid arthritis]
2011 NIHR Horizon Scanning Centre (NIHR HSC) Abraxane for malignant melanoma – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Bevacizumab (Avastin) for triple negative adjuvant breast cancer; in combination with taxane and/or anthracycline chemotherapy
2011 NIHR Horizon Scanning Centre (NIHR HSC) Bevacizumab (Avastin) with octreotide (Sandostatin) for high risk carcinoid tumours – first or second line
2011 Andalusian Health Technology Assessment Area (AETSA) [Use of QALYs in different clinical situations]
2011 Andalusian Health Technology Assessment Area (AETSA) [Impella Recover® 2.5 ventricular assist device]
2011 Andalusian Health Technology Assessment Area (AETSA) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2011 Health Information and Quality Authority (HIQA) A health technology assessment of prion filtration of red cell concentrates to reduce the risk of variant Creutzfeldt-Jakob disease transmission in Ireland
2011 NIHR Horizon Scanning Centre (NIHR HSC) Cetuximab (Erbitux) in combination with oxaliplatin, leucovorin and fluorouracil for colorectal cancer - adjuvant
2011 NIHR Horizon Scanning Centre (NIHR HSC) Brivanib for hepatocellular carcinoma – second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Cetuximab (Erbitux) in combination with capecitabine and cisplatin for advanced or metastatic gastric cancer – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Dasatinib (Sprycel) for prostate cancer – in combination with docetaxel
2011 NIHR Horizon Scanning Centre (NIHR HSC) EC145 for folate receptor positive ovarian cancer
2011 NIHR Horizon Scanning Centre (NIHR HSC) Erlotinib (Tarceva) in combination with sorafenib (Nexavar) for unresectable, advanced or metastatic hepatocellular carcinoma – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Heat-activated liposome encapsulated doxorubicin (ThermoDox) for hepatocellular carcinoma – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for prostate cancer – second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Masitinib with gemcitabine for advanced or metastatic pancreatic cancer
2011 NIHR Horizon Scanning Centre (NIHR HSC) Paclitaxel (Paclical) for epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer – second or third line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Dalcetrapib for the prevention of cardiovascular events
2011 NIHR Horizon Scanning Centre (NIHR HSC) Edoxaban tosylate for prevention of stroke and systemic embolic events in non-valvular atrial fibrillation
2011 NIHR Horizon Scanning Centre (NIHR HSC) HHLivC (Human Heterologous Liver Cells) for urea cycle disorders
2011 NIHR Horizon Scanning Centre (NIHR HSC) ThromboLUX™ for determining platelet quality
2011 NIHR Horizon Scanning Centre (NIHR HSC) Rituximab (MabThera) for anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
2011 NIHR Horizon Scanning Centre (NIHR HSC) Odanacatib for post-menopausal osteoporosis – first or second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Tocilizumab (RoACTEMRA) for early rheumatoid arthritis not treated with methotrexate – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Dimethyl fumarate for relapsing-remitting multiple sclerosis
2011 NIHR Horizon Scanning Centre (NIHR HSC) Lacosamide (Vimpat) for epilepsy – first and second line
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol-generating procedures and risk of transmission of acute respiratory infections: a systematic review
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Guidelines and recommendations for ADHD in children and adolescents
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Optimal pre-operative testing and assessment for adult patients undergoing elective surgical procedures: a review of the clinical evidence and guidelines
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Transcatheter aortic valve implantation for aortic stenosis: a review of the clinical effectiveness and guidelines
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Multidisciplinary treatment programs for patients with non-malignant pain: a review of the clinical evidence, cost-effectiveness, and guidelines
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Nabilone for chronic pain management: a review of clinical effectiveness, safety, and guidelines
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Endovascular thermal ablation technologies for treatment of varicose veins: a review of clinical effectiveness, safety, cost-effectiveness, and guidelines
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Combination therapy for pulmonary arterial hypertension: a review of the clinical effectiveness
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Eliglustat tartrate, miglustat, imiglucerase, velaglucerase or a combination of these for the treatment of Gaucher disease: a review of clinical effectiveness and safety
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Triaging patients from the emergency department to other medical centres: a review of the clinical evidence and guidelines
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Surgical stabilization of a flail chest wall]
2011 The Regional Health Technology Assessment Centre (HTA-centrum) [Active mobilization after flexor tendon repairs in zone II of the hand]
2011 NIHR Horizon Scanning Centre (NIHR HSC) IRay™ for wet age related macular degeneration
2011 Technology Assessment Unit of the McGill University Health Centre (MUHC) X-ray versus gamma irradiation of blood components for prevention of transfusion-associated graft versus host disease: a brief report
2011 Technology Assessment Unit of the McGill University Health Centre (MUHC) The use of Lactobacillus probiotics in the prevention of antibiotic associated clostridium difficile diarrhea
2011 Technology Assessment Unit of the McGill University Health Centre (MUHC) Drug eluting stents. What should be the indications for their use at the MUHC?
2011 Technology Assessment Unit of the McGill University Health Centre (MUHC) Subglottic secretion drainage endotracheal tubes for prevention of ventilator-associated pneumonia
2011 Technology Assessment Unit of the McGill University Health Centre (MUHC) Aortic valve bypass (apicoaortic conduit) in adult degenerative aortic stenosis
2011 NIHR Horizon Scanning Centre (NIHR HSC) Bevacizumab (Avastin) for triple negative adjuvant breast cancer; in combination with taxane and/or anthracycline chemotherapy
2011 NIHR Horizon Scanning Centre (NIHR HSC) Cetuximab (Erbitux) in combination with oxaliplatin, leucovorin and fluorouracil for colorectal cancer - adjuvant
2011 NIHR Horizon Scanning Centre (NIHR HSC) Cetuximab (Erbitux) in combination with capecitabine and cisplatin for advanced or metastatic gastric cancer – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Dasatinib (Sprycel) for prostate cancer – in combination with docetaxel
2011 NIHR Horizon Scanning Centre (NIHR HSC) EC145 for folate receptor positive ovarian cancer
2011 NIHR Horizon Scanning Centre (NIHR HSC) Erlotinib (Tarceva) in combination with sorafenib (Nexavar) for unresectable, advanced or metastatic hepatocellular carcinoma – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Heat-activated liposome encapsulated doxorubicin (ThermoDox) for hepatocellular carcinoma – first line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Ipilimumab (Yervoy) for prostate cancer – second line
2011 NIHR Horizon Scanning Centre (NIHR HSC) Masitinib with gemcitabine for advanced or metastatic pancreatic cancer